Expression of WT1 gene in bone marrow mononuclear cells of patients with myelodysplastic syndromes
10.3760/cma.j.issn.1009-9921.2018.11.008
- VernacularTitle:骨髓增生异常综合征患者骨髓单个核细胞WT1基因表达的研究
- Author:
Jing XIE
1
;
Yujuan HUANG
;
Peimin SHI
Author Information
1. 225400,江苏省泰兴市人民医院血液科
- Keywords:
Myelodysplastic syndromes;
WT1 gene;
Cytogenetics;
Prognosis;
Treatment outcome
- From:
Journal of Leukemia & Lymphoma
2018;27(11):675-677
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the relationship between the expression of WT1 gene in bone marrow mononuclear cells and the cytogenetic characteristics, curative effect and prognosis in patients with myelodysplastic syndromes (MDS). Methods The quantitative expression of WT1 gene was detected by real-time quantitative polymerase chain reaction (RQ-PCR) in bone marrow mononuclear cells of 115 MDS patients who were admitted to Taixing People's Hospital from August 2010 to March 2018, and the relationship between the expression of WT1 gene and the cytogenetic characteristics, curative effect and prognosis were evaluated. Results WT1 gene was highly expressed in 80 cases (69.6 %), lowly expressed in 15 cases (13.0 %), and unexpressed in 20 cases (17.4 %). Of the 80 patients with high WT1 expression, 56 cases (70.0 %) were refractory anemia with excess blasts (RAEB), and 22 cases (27.7 %) were refractory cytopenia with multilineage dysplasia (RCMD). In 55 patients with very poor cytogenetic prognosis, 44 patients had high expression of WT1 gene, and in 28 patients with poor prognosis, 19 patients had high expression of WT1 gene. The complete remission rate of WT1 gene high expression group [12.5 % (10/80)] was lower than that of low expression group [26.7 % (4/15)] and unexpressed group [40.0 % (8/20)], and the difference of complete remission rate between the three groups was statistically significant (χ2＝ 8.96, P< 0.05). Conclusion MDS patients with high expression of WT1 gene have low remission rate and poor prognosis.
